Dr. Kaveh Hoda

They'll never get to have that benefit of a medicine that could actually work because, again, instead of all the money going into research development, figuring out exactly who benefits and who gets harmed from it and who should have it and who shouldn't, they spent all their money and energy in finding ways to sell it and for as long as possible.

And they painted themselves into a corner at the end, and they couldn't at that point then say, okay, well, actually, Only these small subset of people should use the medication because the risk is then worth it in the small subset. But they couldn't do it. They had to withdraw completely. So it's just so stupid on so many levels. It's such a waste of time.

And they painted themselves into a corner at the end, and they couldn't at that point then say, okay, well, actually, Only these small subset of people should use the medication because the risk is then worth it in the small subset. But they couldn't do it. They had to withdraw completely. So it's just so stupid on so many levels. It's such a waste of time.

And they painted themselves into a corner at the end, and they couldn't at that point then say, okay, well, actually, Only these small subset of people should use the medication because the risk is then worth it in the small subset. But they couldn't do it. They had to withdraw completely. So it's just so stupid on so many levels. It's such a waste of time.

And it's a waste of all the time and effort that went into making the medication again, too. Because again, the concept behind the medication, looking at COX-2 inhibitors, looking at ways to selectively attack the pain pathways, shut down the pain pathways before they cascade into inflammation and pain, it's all smart. It's good.

And it's a waste of all the time and effort that went into making the medication again, too. Because again, the concept behind the medication, looking at COX-2 inhibitors, looking at ways to selectively attack the pain pathways, shut down the pain pathways before they cascade into inflammation and pain, it's all smart. It's good.

And it's a waste of all the time and effort that went into making the medication again, too. Because again, the concept behind the medication, looking at COX-2 inhibitors, looking at ways to selectively attack the pain pathways, shut down the pain pathways before they cascade into inflammation and pain, it's all smart. It's good.

And now, to my knowledge, I don't know if people are even thinking about this anymore. And, like, we still have problems with NSAIDs. NSAIDs still cause problems. Lots of health problems still come from them. Advil, Aleve, Ibuprofen, they still cause me headaches because I have to go and take care of people bleeding because of them. They cause heart issues, kidney problems, liver problems.

And now, to my knowledge, I don't know if people are even thinking about this anymore. And, like, we still have problems with NSAIDs. NSAIDs still cause problems. Lots of health problems still come from them. Advil, Aleve, Ibuprofen, they still cause me headaches because I have to go and take care of people bleeding because of them. They cause heart issues, kidney problems, liver problems.

And now, to my knowledge, I don't know if people are even thinking about this anymore. And, like, we still have problems with NSAIDs. NSAIDs still cause problems. Lots of health problems still come from them. Advil, Aleve, Ibuprofen, they still cause me headaches because I have to go and take care of people bleeding because of them. They cause heart issues, kidney problems, liver problems.

Like, people should be—we should be researching new pain medications and— worrying about how to do that right, as opposed to how to make as much money off of it as possible. But that's not where we are. It's not who we are. So I don't know why I'm saying this.

Like, people should be—we should be researching new pain medications and— worrying about how to do that right, as opposed to how to make as much money off of it as possible. But that's not where we are. It's not who we are. So I don't know why I'm saying this.

Like, people should be—we should be researching new pain medications and— worrying about how to do that right, as opposed to how to make as much money off of it as possible. But that's not where we are. It's not who we are. So I don't know why I'm saying this.

How much do we know?

How much do we know?

How much do we know?

Yeah. Okay.

Yeah. Okay.

Yeah. Okay.

Striking imagery.